Epigenomics AG. (7/12/17). "Press Release: Epigenomics AG – Voluntary Public Takeover Offer by Summit Hero Holding Not Successful". Berlin.

	Organisation	Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
	Group	Epigenomics (Group)
	Organisation 2	Summit Hero Holding GmbH
	Group	Cathay Fortune International Co. Ltd. (CFIC)
	Product	Epi proColon® blood test
	Product 2	investment banking
	Index term	Epigenomics–SEVERAL: investment, 201704–201707 public cash takeover offer €7.52/share FAILED valuing ECX at €171m incl net cash by CFUC + Biochain
	Person	Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic)
	Person 2	Vogt, Peter (Epigenomics 201601 Investor + Public Relations)

Summit Hero Holding GmbH (“bidder”) announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, the minimum acceptance threshold of 75.0 percent has not been reached.

Greg Hamilton, CEO of Epigenomics, commented: „It is unfortunate that the takeover offer has not been successful. We now will carefully explore alternative financing options for Epigenomics in order to successfully commercialize our products and develop innovative cancer tests.”

Contact:

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon®, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, please visit www.epigenomics.com.

Record changed: 2023-06-05